Cite
HARVARD Citation
D'Haens, G. et al. (2017). Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis. Alimentary pharmacology & therapeutics. 46 (3), pp. 292-302. [Online].